The efficacy and safety of adalimumab in ocular inflammatory disease

References

• Levy-Clarke G, Jabs DA, Read RW, Rosenbaum JT, Vitale A, Van Gelder RN. Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders. Ophthalmology. 2014;121:785–796. e3.
   PubMed Web of Science ®Google Scholar
• Sen ES, Sharma S, Hinchcliffe A, Dick AD, Ramanan AV. Use of adalimumab in refractory non-infectious childhood chronic uveitis: efficacy in ocular disease – a case cohort interventional study. Rheumatology (Oxford). 2012;51:2199–2203.
   PubMed Web of Science ®Google Scholar
• Kotaniemi K, Saila H, Kautiainen H. Long-term efficacy of adalimumab in the treatment of uveitis associated with juvenile idiopathic arthritis. Clin Ophthalmol. 2011;5:1425–1429.
   PubMedGoogle Scholar
• Trachana M, Pratsidou-Gertsi P, Pardalos G, Kozeis N, Badouraki M, Kanakoudi-Tsakalidou F. Safety and efficacy of adalimumab treatment in Greek children with juvenile idiopathic arthritis. Scand J Rheumatol. 2011;40:101–107.
   PubMed Web of Science ®Google Scholar
• Tynjala P, Kotaniemi K, Lindahl P, et al. Adalimumab in juvenile idiopathic arthritis-associated chronic anterior uveitis. Rheumatology (Oxford). 2008;47:339–344.
   PubMed Web of Science ®Google Scholar
• Vazquez-Cobian LB, Flynn T, Lehman TJ. Adalimumab therapy for childhood uveitis. J Pediatr. 2006;149:572–575.
   PubMed Web of Science ®Google Scholar
• Simonini G, Taddio A, Cattalini M, et al. Prevention of flare recurrences in childhood-refractory chronic uveitis: an open-label comparative study of adalimumab versus infliximab. Arthritis Care Res. 2011;63:612–618.
   PubMed Web of Science ®Google Scholar
• Zannin ME, Birolo C, Gerloni VM, et al. Safety and efficacy of infliximab and adalimumab for refractory uveitis in juvenile idiopathic arthritis: 1-year followup data from the Italian Registry. J Rheumatol. 2013;40:74–79.
   PubMed Web of Science ®Google Scholar
• Adams AB, Kazim M, Lehman TJ. Treatment of orbital myositis with adalimumab (Humira). J Rheumatol. 2005;32:1374–1375.
   PubMed Web of Science ®Google Scholar
• Callejas-Rubio JL, Ortego-Centeno N, Lopez-Perez L, Benticuaga MN. Treatment of therapy-resistant sarcoidosis with adalimumab. Clin Rheumatol. 2006;25:596–597.
   PubMed Web of Science ®Google Scholar
• van Laar JA, Missotten T, van Daele PL, Jamnitski A, Baarsma GS, van Hagen PM. Adalimumab: a new modality for Behcet’s disease? Ann Rheum Dis. 2007;66:565–566.
   PubMed Web of Science ®Google Scholar
• Winterhalter S, Niehues T. TNFalpha-blocking agents or conventional immunosuppressive drugs in the therapy of children with uveitis? – an evidence based approach. Klin Padiatr. 2008;220:342–347.
   PubMed Web of Science ®Google Scholar
• Diaz-Llopis M, Garcia-Delpech S, Salom D, et al. Adalimumab therapy for refractory uveitis: a pilot study. J Ocul Pharmacol Ther. 2008;24:351–361.
   PubMed Web of Science ®Google Scholar
• Biester S, Deuter C, Michels H, et al. Adalimumab in the therapy of uveitis in childhood. Br J Ophthalmol. 2007;91:319–324.
   PubMed Web of Science ®Google Scholar
• Suhler EB, Lowder CY, Goldstein DA, et al. Adalimumab therapy for refractory uveitis: results of a multicentre, open-label, prospective trial. Br J Ophthalmol. 2013;97:481–486.
   PubMed Web of Science ®Google Scholar
• Dobner BC, Max R, Becker MD, et al. A three-centre experience with adalimumab for the treatment of non-infectious uveitis. Br J Ophthalmol. 2013;97:134–138.
   PubMed Web of Science ®Google Scholar
• Diaz-Llopis M, Salom D, Garcia-de-Vicuna C, et al. Treatment of refractory uveitis with adalimumab: a prospective multicenter study of 131 patients. Ophthalmology. 2012;119:1575–1581.
   PubMed Web of Science ®Google Scholar
• Rudwaleit M, Rodevand E, Holck P, et al. Adalimumab effectively reduces the rate of anterior uveitis flares in patients with active ankylosing spondylitis: results of a prospective open-label study. Ann Rheum Dis. 2009;68:696–701.
   PubMed Web of Science ®Google Scholar
• Garcia-De-Vicuna C, Diaz-Llopis M, Salom D, et al. Usefulness of adalimumab in the treatment of refractory uveitis associated with juvenile idiopathic arthritis. Mediators Inflamm. 2013;2013:560632.
   PubMed Web of Science ®Google Scholar
• Doycheva D, Zierhut M, Blumenstock G, et al. Immunomodulatory therapy with tumour necrosis factor alpha inhibitors in children with antinuclear antibody-associated chronic anterior uveitis: long-term results. Br J Ophthalmol. 2014;98:523–528.
   PubMed Web of Science ®Google Scholar
• Bravo-Ljubetic L, Peralta-Calvo J, Noval S, Pastora-Salvador N, Abelairas-Gomez J, Merino R. Adalimumab therapy for refractory childhood uveitis. J AAPOS. 2013;17:456–459.
   PubMed Web of Science ®Google Scholar
• Simonini G, Taddio A, Cattalini M, et al. Superior efficacy of Adalimumab in treating childhood refractory chronic uveitis when used as first biologic modifier drug: Adalimumab as starting anti-TNF-alpha therapy in childhood chronic uveitis. Pediatr Rheumatol Online J. 2013;11:16.
   PubMed Web of Science ®Google Scholar
• Magli A, Forte R, Navarro P, et al. Adalimumab for juvenile idiopathic arthritis-associated uveitis. Graefes Arch Clin Exp Ophthalmol. 2013;251:1601–1606.
   PubMed Web of Science ®Google Scholar
• Perra D, Alba MA, Callejas JL, et al. Adalimumab for the treatment of Behcet’s disease: experience in 19 patients. Rheumatology (Oxford). 2012;51:1825–1831.
   PubMed Web of Science ®Google Scholar
• Cordero-Coma M, Mendez RS, Blanco AC, Corral AL, Calleja-Antolin S, de Morales JM. Adalimumab for refractory peripheral ulcerative keratitis. J Ophthalmic Inflamm Infect. 2012;2:227–229.
   Google Scholar
• Erckens RJ, Mostard RL, Wijnen PA, Schouten JS, Drent M. Adalimumab successful in sarcoidosis patients with refractory chronic non-infectious uveitis. Graefes Arch Clin Exp Ophthalmol. 2012;250:713–720.
   PubMed Web of Science ®Google Scholar
• Olivieri I, Leccese P, D’Angelo S, et al. Efficacy of adalimumab in patients with Behcet’s disease unsuccessfully treated with infliximab. Clin Exp Rheumatol. 2011;29:S54–S57.
   PubMed Web of Science ®Google Scholar
• Bawazeer A, Raffa LH, Nizamuddin SH. Clinical experience with adalimumab in the treatment of ocular Behcet disease. Ocul Immunol Inflamm. 2010;18:226–232.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov [search results for adalimumab and uvetis studies]. US National Institutes of Health. Available at: https://clinicaltrials.gov/ct2/results?term=%22adalimumab%22+and+%22uveitis%22&Search=Search. Accessed February 24, 2015.
   Google Scholar